Condition: Migraine Disorders · Chronic Migraine · Episodic Migraine · Sponsor: IRCCS National Neurological Institute "C. Mondino" Foundation
Aim of the study was to assess a potential dysfunction of the endocannabidiome system (eCBome) in migraine patients. Migraine patients who will undergo preventive therapy with monoclonal antibodies directed against the calcitonin gene related peptide (mAbs) will be evaluated through a deep phenotyping of peripheral neurochemical biomarkers (eCBome, neuropeptides, cytokines and kynurenine levels, and microRNAs expression). Primary aim is to assess baseline differences among those patients who achieved a reduction of monthly migraine days \>/= 50% after three months of tretament (namely Responders) and those who did not (namely Non-responders).
This description comes directly from the study's public registry record.
Roberto De Icco · 00390382380425 · roberto.deicco@mondino.it
Cinzia Fattore · 00390382380385 · cinzia.fattore@mondino.it
Always discuss trial participation with your own doctor first.
| Headache Science & Neurorehabilitation Unit | Pavia, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06549270